# Phase 1 Open-label Study of 123I-ATT001 in Subjects With Relapsed Glioblastoma

> **NCT06650605** · PHASE1 · COMPLETED · sponsor: **Theragnostics Ltd** · enrollment: 7 (actual)

## Conditions studied

- Glioma Glioblastoma Multiforme

## Interventions

- **DRUG:** 123I-ATT001

## Key facts

- **NCT ID:** NCT06650605
- **Lead sponsor:** Theragnostics Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-04
- **Primary completion:** 2026-03-01
- **Final completion:** 2026-03-01
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06650605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06650605, "Phase 1 Open-label Study of 123I-ATT001 in Subjects With Relapsed Glioblastoma". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT06650605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*